Therapeutic agents specifically delivered by exosomes for cancer treatment
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsJing-Hung Wang, Alexis Forterre, A. C. Matin, Alain Delcayre
Life of this patent
Estimating the term…
Abstract
Provided herein are extracellular vesicle (EV) (a.k.a. exosome) compositions for specifically targeting the delivery of a therapeutic agent to particular cells and/or tissues in a subject, as well as methods of making and methods of using said compositions. The compositions and methods disclosed herein are useful for targeted drug delivery in the treatment of diseases in which a cell surface receptor is overexpressed, such as, for example, cancer.
Claims12
A composition comprising an extracellular-receptor-targeted exosome presenting a targeting moiety on its surface, wherein the exosome comprises:
- (a) a chimeric protein comprising:
- i) a lactadherin leader sequence (LS) for migration to the exosome surface,
- ii) a targeting moiety having high affinity for an extracellular receptor overexpressed in a disease,
- iii) a lactadherin C1-C2 domain, and
- iv) an epitope tag for purification;
- and
- (b) an active agent included in the exosome, wherein the active agent is a functional mRNA encoding ChrR.
Dependencies are inferred from the claim text.